Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. more
Time Frame | JAGX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.45% | -3.35% | -2.97% |
1-Month Return | -9.99% | -3.49% | -0.66% |
3-Month Return | -21.34% | -12.6% | 2.71% |
6-Month Return | -78.06% | -6.91% | 7.21% |
1-Year Return | -91.02% | 1.19% | 23.04% |
3-Year Return | -99.98% | -0.21% | 28.43% |
5-Year Return | -99.99% | 33.09% | 82.88% |
10-Year Return | -100% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.78M | 9.38M | 4.33M | 11.96M | 9.76M | [{"date":"2019-12-31","value":48.3,"profit":true},{"date":"2020-12-31","value":78.5,"profit":true},{"date":"2021-12-31","value":36.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.64,"profit":true}] |
Cost of Revenue | 3.82M | 3.28M | 2.33M | 2.02M | 2.04M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":85.96,"profit":true},{"date":"2021-12-31","value":61.14,"profit":true},{"date":"2022-12-31","value":52.91,"profit":true},{"date":"2023-12-31","value":53.38,"profit":true}] |
Gross Profit | 1.96M | 6.11M | 2.00M | 9.94M | 7.72M | [{"date":"2019-12-31","value":19.72,"profit":true},{"date":"2020-12-31","value":61.44,"profit":true},{"date":"2021-12-31","value":20.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.73,"profit":true}] |
Gross Margin | 33.93% | 65.05% | 46.18% | 83.11% | 79.13% | [{"date":"2019-12-31","value":40.82,"profit":true},{"date":"2020-12-31","value":78.27,"profit":true},{"date":"2021-12-31","value":55.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.21,"profit":true}] |
Operating Expenses | 26.91M | 27.41M | 41.08M | 44.35M | 42.02M | [{"date":"2019-12-31","value":60.67,"profit":true},{"date":"2020-12-31","value":61.8,"profit":true},{"date":"2021-12-31","value":92.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.73,"profit":true}] |
Operating Income | (24.95M) | (21.30M) | (39.07M) | (34.41M) | (34.29M) | [{"date":"2019-12-31","value":-2494811100,"profit":false},{"date":"2020-12-31","value":-2130400000,"profit":false},{"date":"2021-12-31","value":-3907400000,"profit":false},{"date":"2022-12-31","value":-3441500000,"profit":false},{"date":"2023-12-31","value":-3429100000,"profit":false}] |
Total Non-Operating Income/Expense | (19.31M) | (15.30M) | (21.95M) | (26.70M) | (16.38M) | [{"date":"2019-12-31","value":-1931197300,"profit":false},{"date":"2020-12-31","value":-1529700000,"profit":false},{"date":"2021-12-31","value":-2194700000,"profit":false},{"date":"2022-12-31","value":-2670300000,"profit":false},{"date":"2023-12-31","value":-1637800000,"profit":false}] |
Pre-Tax Income | (38.53M) | (33.81M) | (52.60M) | (48.40M) | (41.90M) | [{"date":"2019-12-31","value":-3852943600,"profit":false},{"date":"2020-12-31","value":-3380900000,"profit":false},{"date":"2021-12-31","value":-5260000000,"profit":false},{"date":"2022-12-31","value":-4839500000,"profit":false},{"date":"2023-12-31","value":-4190100000,"profit":false}] |
Income Taxes | 10.00K | 2.98M | 7.65M | (941.00K) | (601.00K) | [{"date":"2019-12-31","value":0.13,"profit":true},{"date":"2020-12-31","value":38.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-12.3,"profit":false},{"date":"2023-12-31","value":-7.86,"profit":false}] |
Income After Taxes | (38.54M) | (36.79M) | (60.25M) | (47.45M) | (41.30M) | [{"date":"2019-12-31","value":-3853943600,"profit":false},{"date":"2020-12-31","value":-3679100000,"profit":false},{"date":"2021-12-31","value":-6025100000,"profit":false},{"date":"2022-12-31","value":-4745400000,"profit":false},{"date":"2023-12-31","value":-4130000000,"profit":false}] |
Income From Continuous Operations | (38.54M) | (33.81M) | (52.60M) | (48.40M) | (40.82M) | [{"date":"2019-12-31","value":-3853943600,"profit":false},{"date":"2020-12-31","value":-3380900000,"profit":false},{"date":"2021-12-31","value":-5260000000,"profit":false},{"date":"2022-12-31","value":-4839500000,"profit":false},{"date":"2023-12-31","value":-4082400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (38.54M) | (36.79M) | (60.25M) | (47.45M) | (41.30M) | [{"date":"2019-12-31","value":-3853943600,"profit":false},{"date":"2020-12-31","value":-3679100000,"profit":false},{"date":"2021-12-31","value":-6025100000,"profit":false},{"date":"2022-12-31","value":-4745400000,"profit":false},{"date":"2023-12-31","value":-4130000000,"profit":false}] |
EPS (Diluted) | - | (5.55K) | (88.50) | (51.43) | (36.63) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-555300,"profit":false},{"date":"2021-12-31","value":-8850,"profit":false},{"date":"2022-12-31","value":-5142.97,"profit":false},{"date":"2023-12-31","value":-3662.81,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
JAGX | |
---|---|
Cash Ratio | 0.67 |
Current Ratio | 1.84 |
Quick Ratio | 1.36 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
JAGX | |
---|---|
ROA (LTM) | -34.53% |
ROE (LTM) | -290.94% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
JAGX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.78 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.23 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
JAGX | |
---|---|
Trailing PE | 0.04 |
Forward PE | NM |
P/S (TTM) | 1.00 |
P/B | 0.76 |
Price/FCF | NM |
EV/R | 2.99 |
EV/Ebitda | NM |
PEG | NM |
Jaguar Animal Health Inc (JAGX) share price today is $0.8731
Yes, Indians can buy shares of Jaguar Animal Health Inc (JAGX) on Vested. To buy Jaguar Animal Health Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JAGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Jaguar Animal Health Inc (JAGX) via the Vested app. You can start investing in Jaguar Animal Health Inc (JAGX) with a minimum investment of $1.
You can invest in shares of Jaguar Animal Health Inc (JAGX) via Vested in three simple steps:
The 52-week high price of Jaguar Animal Health Inc (JAGX) is $21.6. The 52-week low price of Jaguar Animal Health Inc (JAGX) is $0.84.
The price-to-earnings (P/E) ratio of Jaguar Animal Health Inc (JAGX) is 0.0426
The price-to-book (P/B) ratio of Jaguar Animal Health Inc (JAGX) is 0.76
The dividend yield of Jaguar Animal Health Inc (JAGX) is 0.00%
The market capitalization of Jaguar Animal Health Inc (JAGX) is $10.15M
The stock symbol (or ticker) of Jaguar Animal Health Inc is JAGX